Clinical Trials

Multiple completed clinical trials, ranging from Phase 1 to Phase 4, have evaluated thimerosal and thimerosal-free formulations across diverse medical conditions. Investigated applications include contact dermatitis patch testing, thimerosal-free influenza vaccines, post-vaccination mercury metabolism, and sublingual therapy for symptomatic SARS-CoV-2 infection. These studies were supported by various industry and institutional sponsors, including GlaxoSmithKline, Allerderm, Beech Tree Labs, Inc., and the National Institute of Allergy and Infectious Diseases.

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT04522830 COMPLETED
SARS-CoV-2 Infection
Beech Tree Labs, Inc.
 2020-07-30 PHASE2
NCT00980005 COMPLETED
Influenza
GlaxoSmithKline
 2009-10-13 PHASE3
NCT00778895 COMPLETED
Influenza
GlaxoSmithKline
 2008-11-10 PHASE2
NCT00764790 COMPLETED
Influenza
GlaxoSmithKline
 2008-10-01 PHASE3
NCT00612768 COMPLETED
Dermatitis, Contact
Allerderm
 2008-01 PHASE2
NCT00795951 Completed
Dermatitis Contact
Allerderm
 2008-11 Phase 4
NCT00727428 COMPLETED
Influenza
GlaxoSmithKline
 2008-08-05 PHASE1
NCT00333398 COMPLETED
Influenza
National Institute of Allergy and Infectious Diseases (NIAID)
 2006-06 PHASE3

(data from https://clinicaltrials.gov, updated on 2021-04-13)

Check the Thimerosal product page for in-depth specifications, including solubility, stock solutions, MOA, and working concentrations.

Compliance for Clinical Use

Mechanism and Biochemical Profile

Thimerosal metabolizes to ethylmercury which binds to reactive sulfhydryl groups on vital bacterial and fungal enzymes, disrupting key metabolic pathways and membrane integrity to inhibit microbial growth. This broad-spectrum antimicrobial mechanism underpins its evaluation in clinical settings, including its application as a vaccine preservative, diagnostic contact allergen, and potential antiviral intervention in SARS-CoV-2 infection.

Appendix RUO and cGMP Quality Standards

Quality Dimension RUO (Research Use Only) cGMP (Current Good Manufacturing Practice)
Clinical Applicability Prohibited in human clinical trials or medical diagnostics. Mandatory for human clinical trials (Phase I–III) and therapies.
Regulatory Status Non-regulated grade; exempt from drug manufacturing laws. Legally enforced by health authorities (e.g., FDA, EMA, NMPA).
Facility Environment Unclassified analytical or research laboratories. Validated Cleanrooms (ISO Class 5–8) with continuous monitoring.
Quality Control Basic purity and activity testing. Rigorous safety release testing (Sterility, Endotoxin, Mycoplasma).
Process Validation Basic equipment calibration; no process validation required. Full qualification (IQ/OQ/PQ) and complete batch records.
Quality Assurance Vendor self-declared without required formal QMS. Mandatory QA/QC unit, Change Control, CAPA, and vendor audits.
Regulatory Impact High risk of IND rejection if used as a critical raw material. Required for IND/NDA filings, supported by Drug Master Files (DMF).

Footnotes

Regulatory Note: Governed by FDA (21 CFR Parts 210/211/312), EMA (EudraLex Vol 4), ICH Guidelines (E6/Q7/Q9/Q10), and compendial standards (USP <71>/<85>/<1043>).

Jump to

Note: Technical data last updated: Sep 1, 2026.